EP1674454A1 - Substituiertes 2-amino-[1,2,4]triazolo[1,5-a]pyrimidinderivat und dessen verwendung - Google Patents

Substituiertes 2-amino-[1,2,4]triazolo[1,5-a]pyrimidinderivat und dessen verwendung Download PDF

Info

Publication number
EP1674454A1
EP1674454A1 EP04792462A EP04792462A EP1674454A1 EP 1674454 A1 EP1674454 A1 EP 1674454A1 EP 04792462 A EP04792462 A EP 04792462A EP 04792462 A EP04792462 A EP 04792462A EP 1674454 A1 EP1674454 A1 EP 1674454A1
Authority
EP
European Patent Office
Prior art keywords
group
amino
substituted
triazolo
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04792462A
Other languages
English (en)
French (fr)
Other versions
EP1674454A4 (de
Inventor
Hiroshi Kuramochi
Akira Masuda
Kazuhisa Shimizu
Eriko Toyoda
Kazuhiro Tokunaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Publication of EP1674454A1 publication Critical patent/EP1674454A1/de
Publication of EP1674454A4 publication Critical patent/EP1674454A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • the present invention relates to an immunosuppresant or an immunotolerance inducer. More specifically, the present invention relates to a drug containing a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative which can be used for the treatment or prevention of autoimmune diseases, allergic diseases, diseases associated with tissue inflammation, rejection against organ transplantation or bone marrow transplantation or graft versus host reaction as an immunosuppresant. The present invention also relates to a drug containing a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative which can be used for successfully engrafting an organ or bone marrow transplanted to a patient as an immunotolerance inducer.
  • immunosuppresants for example, steroid drugs, ciclosporin A, tacrolimus, mycophenolate mofetil, mizoribine, deoxyspergualin, etc. are used for the treatment and prevention of transplantation rejection, autoimmune diseases, allergic diseases and various autoimmune diseases, etc.
  • Ciclosporin A and tacrolimus inhibit the production of cytokine which is a regulator of lymphocyte and thereby show immune inhibition action.
  • Ciclosporin A is administered for inhibiting transplantation rejection against kidney transplantation, liver transplantation, bone marrow transplantation and heart transplantation, Behcet's disease, psoriasis, aplastic anemia, nephrotic syndrome.
  • Tacrolimus is administered for inhibiting transplantation rejection against kidney transplantation, liver transplantation, bone marrow transplantation and heart transplantation, atopic dermatitis, myasthenia gravis as a stronger cytokine production inhibitant.
  • Mycophenolate mofetil and mizoribine show immune inhibition action through antagonistic action on nucleic-acid metabolism of lymphocyte.
  • Mycophenolate mofetil is used for inhibiting rejection against kidney transplantation, and mizoribine is used for nephrotic syndrome, lupus nephritis, chronic rheumatoid arthritis.
  • Deoxyspergualin shows immune inhibition action by inhibiting antibody production and the function of lymphocyte, and is used for the treatment of rejection after kidney transplantation.
  • Immunosuppresant is also effective for autoimmune diseases other than the diseases mentioned above, and for example, ciclosporin A has been reported to be effective for diseases such as atopic dermatosis, autoimmune hepatitis, Crohn's disease, colitis ulcerosa, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, insulin-dependent diabetes besides the adapted diseases.
  • Non-Patent Document 1 Non-Patent Document 1
  • Non-Patent Document 2 Accumulation of dendritic cells which are antigen presenting cells is also recognized at lesioned arthrosis part of a patient in rheumatism, an inflammatory disease, and it is considered that presentation of an antigen participates in the onset and aggravation thereof (Non-Patent Document 2).
  • T cell when T cell recognizes a cell developing a target antigen, it is performed through MHC (major histocompatibiliy complex), and therefore presentation of an antigen is also considered to participate in activation of T cells and tissue damage at lesioned site in autoimmune diseases and inflammatory diseases (Non-Patent Document 3).
  • MHC major histocompatibiliy complex
  • Non-Patent Document 4 discloses that immune tolerance is induced by differences of maturation phase among antigen-presenting dendritic cells. It is considered that matured dendritic cells induce effector T lymphocytes having cytotoxic activity and cytokine production activity whereas immature dendritic cells induce regulatory or inhibitor T cells and have a big role on induction and maintenance of immune tolerance.
  • Antigen presentation is a function specific to immune system, and it is considered that substances which specifically inhibit antigen presentation inhibition/modification action do not exhibit actions other than the immune system, that is, side effects recognized in presently known immunosuppresants.
  • An object of the present invention is to provide an immunosuppresant or an immunotolerance inducer having little side effect which inhibits aberration or excessive immune response by inhibiting or modifying the antigen presentation.
  • the present inventors have conducted intensive studies to solve the above-mentioned problems and have found that substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives inhibit antigen presentation by antigen presenting cells and have immune inhibition action and that the compound inhibits the lymphocyte proliferation response and can be applied as a therapeutic agent or a prophylactic agent for immune disorders, and have completed the present invention.
  • the present inventors have found that the compound inhibits the expression of the antigen presentation conjugated molecule which participates in antigen presentation and that it can be used as an immunotolerance inducer and have completed the present invention.
  • the present inventors have also found that the compound has cell proliferation inhibitory activity on cells of lymphoma cell line and that it can be used as an antineoplastic drug and have completed the present invention.
  • the present invention relate to a drug comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative represented by the general formula (I):
  • Ar represents a phenyl group which may have a substituent or a 5- or 6-membered aromatic heterocyclic group which contains one hetero atom and may have a substituent
  • R represents a (C1-C6) alkyl group which may be substituted with a substituent selected from the substituent group consisting of a halogeno group, a cyano group, a nitro group, a hydroxyl group, a (C1-C6) alkoxyl group, a benzyloxy group, a phenyl group and a 5- or 6-membered aromatic heterocyclic group which contains one hetero atom, a (C2-C7) alkoxycarbonyl group which may be substituted with a substituent, a (C1-C13) aliphatic acyl group which may have 1 to 3 same or different substituents, an amino acid group in which the N-terminal may be protected or a 3- to 7-membered cyclic acyl group which may have 1 to 3 same or different substituent
  • the present invention relates to an antigen presentation inhibitor comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above. Furthermore, the present invention relates to an immunosuppresant or an immunotolerance inducer comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above.
  • the present invention relates to a therapeutic agent or a prophylactic agent for transplant rejection reaction or graft versus host reaction diseases comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above. Furthermore, the present invention relates to a therapeutic agent or a prophylactic agent for autoimmune diseases comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above.
  • the present invention relates to a therapeutic agent or a prophylactic agent for rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, discoid lupus erythematosus, Sjogren's syndrome, Crohn's disease, colitis ulcerosa, idiopathic thrombocytopenia, aplastic anemia, autoimmune hepatitis, insulin-dependent diabetes, myasthenia gravis, polymyositis, scleroderma, mixed connective tissue disease, ankylosing spondylitis or chronic thyroiditis comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above.
  • the present invention relates to a therapeutic agent or a prophylactic agent for allergic diseases comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above. Furthermore, the present invention relates to a therapeutic agent or a prophylactic agent for atopic dermatosis, pollinosis, contact hypersensitivity, asthma, psoriasis or anaphylaxis comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above.
  • the present invention relates to a therapeutic agent or a prophylactic agent for inflammatory diseases comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above.
  • the present invention relates to a therapeutic agent or a prophylactic agent for Behcet's disease, polyarteritis, sarcoidosis, glomerulonephritis, nephrotic syndrome, intractable vasculitis or Wegener's syndrome comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above.
  • the present invention relates to a cell proliferation inhibitor comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above. Furthermore, the present invention relates to an antineoplastic drug comprising as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or a pharmaceutically acceptable salt thereof mentioned above. Furthermore, the present invention relate to a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative represented by the general formula (III):
  • A represents a phenyl group which may be substituted with 1 to 3 same or different substituents selected from the substituent group (A) consisting of a halogeno group, a hydroxyl group, a (C1-C6) alkyl group, a cyano group, a nitro group, a (C1-C6) alkoxyl group, a benzyloxy group, an amino group, a (C1-C7) acylamino group and a methylenedioxy group or a 5- or 6-membered aromatic heterocyclic group which contains one hetero atom and may be substituted with 1 to 3 same or different substituents selected from the substituent group (A); and W represents a (C1-C6) alkyl group which may be substituted with one substituent selected from the substituent group consisting of a halogeno group, a hydroxyl group, a (C1-C6) alkoxyl group, a phenyl group and a 5- or 6-membered aromatic heterocyclic
  • the present invention relates to a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative which is 3-benzenesulfonyl-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propionamide, 3-benzenesulfonyl-N-(7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propionamide, (S)-2-(tert-butoxycarbonyl)amino-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)butylamide, (S)-2-amino-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)butylamide or (S)
  • the substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl urea derivatives represented by general formula (I) of the present invention or pharmaceutically acceptable salts thereof show antigen presentation inhibitory effect and lymphocyte function inhibitory effect and are useful as a drug for the treatment or prevention of autoimmune diseases, transplantation rejection, graft versus host reaction, allergic diseases or inflammatory diseases. In addition, they inhibit expression of a costimulatory molecule participating in antigen presentation and are useful as a drug for immune tolerance induction.
  • they show excellent activity in in vitro and in vivo immune inhibition activity test and can be used as prophylactic and/or therapeutic drugs for rejection reaction in the transplantation of organs and bone marrow and/or graft versus host reaction, autoimmune diseases, allergic diseases and/or of inflammatory diseases, and an immunotolerance inducer on transplanted organs and transplanted bone marrow.
  • they have cell proliferation inhibitory effect and can be used as a drug for the treatment of malignant tumor.
  • the drug of the present invention comprises as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative represented by the above general formula (I), wherein Ar represents a phenyl group which may have a substituent or a 5- or 6-membered aromatic heterocyclic group which contains one hetero atom and may have a substituent; and R represents a (C1-C6) alkyl group which may be substituted with a substituent selected from the substituent group consisting of a halogeno group, a cyano group, a nitro group, a hydroxyl group, a (C1-C6) alkoxyl group, a benzyloxy group, a phenyl group and a 5- or 6-membered aromatic heterocyclic group which contains one hetero atom, a (C2-C7) alkoxycarbonyl group which may be substituted with a substituent, a (C1-C13) aliphatic acyl group which may have 1 to
  • Preferable substituent Ar in the general formula (I) includes 1-3 same or different groups selected from the substituent group (A) consisting of a halogeno group, a hydroxyl group, a (C1-C6) alkyl group, a cyano group, a nitro group, a (C1-C6) alkoxyl group, a benzyloxyl group, an amino group, a (C1-C7) acylamino group and a methylenedioxy group.
  • substituent group (A) consisting of a halogeno group, a hydroxyl group, a (C1-C6) alkyl group, a cyano group, a nitro group, a (C1-C6) alkoxyl group, a benzyloxyl group, an amino group, a (C1-C7) acylamino group and a methylenedioxy group.
  • the substituent on (C1-C6) alkyl group in R of general formula (I) includes a substituent selected from the substituent group consisting of a halogeno group, a cyano group, a nitro group, a hydroxyl group, a (C1-C6) alkoxyl group, a benzyloxy group, a phenyl group and a 5- or 6-membered aromatic heterocyclic group which contains one hetero atom, and preferably includes one substituent selected from the substituent group consisting of a halogeno group, a hydroxyl group, a (C1-C6) alkoxyl group, a phenyl group and a 5- or 6-membered aromatic heterocyclic group which contains one hetero atom.
  • the substituent on (C2-C7) alkoxycarbonyl group in R of general formula (I) preferably includes one substituent selected from the substituent group consisting of a phenyl group, a methoxyphenyl group and a 5- or 6-membered aromatic heterocyclic group which contains one hetero atom.
  • the substituent on (C1-C13) aliphatic acyl group in R of general formula (I) preferably includes 1-3 same or different groups selected from the substituent group consisting of a halogeno group, a hydroxyl group, an oxo group, a (C1-C6) alkoxyl group, a (C1-C7) acyl group, a (C1-C7) acyloxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group, a nitro group, a (C1-C6) alkylsulfanyl group, a benzylsulfanyl group, an arylsulfanyl group, a (C1-C6) alkylsulfonyl group, an arylsulfonyl group, a (C1-C6) alkoxycarbonyl group, an amino group, a (C1-C6) alkylamino group, a di(C1
  • the amino acid group in which N-terminal may by protected in R of general formula (I) includes an ⁇ -amino acid group in which N-terminal may by protected, and preferably includes an ⁇ -amino acid group represented by the following general formula (II):
  • T represents a hydrogen atom, a methyl group, an ethyl group, a propyl group or an isopropyl group
  • Q represents a hydrogen atom, a (C1-C7) acyl group or a (C1-C6) alkoxycarbonyl group.
  • the 3- to 7-membered cyclic acyl group which may have 1 to 3 same or different substituents in R of general formula (I) is preferably Z-CO-, wherein Z represents an aromatic hydrocarbon group which may have a substituent or a 5- or 6-membered saturated or unsaturated heterocyclic group which contains 1 to 4 hetero atoms independently selected from N, O and S and may have a substituent, and the substituent preferably includes 1 to 3 same or different substituents selected from the substituent group (B) consisting of a (C1-C6) alkyl group, a halogeno group, a hydroxyl group, an oxo group, a trifluoromethyl group, a cyano group, a nitro group, a (C1-C6) alkoxyl group, a benzyloxy group, a (C1-C6) alkylsulfanyl group, a (C1-C6) alkoxycarbonyl group, an amino group, a di(C1
  • the 5- or 6-membered aromatic heterocyclic group which contains one hetero atom in Ar of a compound represented by general formula (I) in the drug of the present invention is a 5- or 6-membered aromatic heterocyclic group containing one hetero atom which is preferably selected from N, O and S independently, and specifically includes a furan-2-yl group, a furan-3-yl group, a thiophen-2-yl group, a thiophen-3-yl group, a pyridin-2-yl group, a pyridin-3-yl group or a pyridin-4-yl group, and preferably it is a thiophen-2-yl group, a thiophen-3-yl group, a pyridin-3-yl group or a pyridin-4-yl group, and more preferably it is a thiophen-2-yl group or a thiophen-3-yl group.
  • the halogeno group in the present invention is a fluoro group, a chloro group, a bromo group or an iodo group, and preferably it is a fluoro group or a chloro group, and more preferably it is a fluoro group.
  • the (C1-C6) alkyl group in the present invention refers to a linear, branched chain or cyclic alkyl group having 1 to 6 carbon atoms and includes, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a tert-butyl group, a pentyl group, an isopentyl group, a 2-methylbutyl group, a neopentyl group, a 1-ethylpropyl group, a hexyl group, a 4-methylpentyl group, a 3-methylpentyl group, a 2-methylpentyl group, a 1-methylpentyl group, a 3,3-dimethylbutyl group, a 2,2-dimethylbutyl group, a 1,1-dimethylbutyl group, a 1,2-dimethylbutyl group, a 1,3
  • the (C1-C6) alkoxy group in the present invention refers to a group in which a (C1-C6) alkyl group as mentioned above is linked with an oxygen atom and includes, for example, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a tert-butoxy group, a pentyloxy group, an isopentyloxy group, a 2-methylbutoxy group, a neopentyloxy group, a 1-ethylpropoxy group, a hexyloxy group, a 4-methylpentyloxy group, a 3-methylpentyloxy group, a 2-methylpentyloxy group, a 1-methylpentyloxy group, a 3,3-dimethylbutoxy group, a 2,2-dimethylbutoxy group, a 1,1-dimethylbutoxy group, a 1,2-dimethylbutoxy group, a 1,3
  • it is a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group a butoxy group, an isobutoxy group or a tert-butoxy group, and preferably it is a methoxy group, an ethoxy group or an isopropoxy group.
  • it is a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, an isobutoxycarbonyl group or a tert-butoxycarbonyl group, and more preferably it is an ethoxycarbonyl group or a tert-butoxycarbonyl group.
  • it is a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a tert-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a hexyl group, a 4-methylpentyl group, a 3,3-dimethylbutyl group, a 5-methylhexyl group, a 4,4-dimethylpentyl group, a cyclopentyl group, a cyclohexyl group, a vinyl group, a propenyl group or a 2-methylpropenyl group, and more preferably it is a methyl group, an ethyl group, a propyl group, a tert-butyl group, an isopentyl group, a 4-methylpentyl group, a vinyl group, a propenyl group,
  • the (C1-C7) acyl group in the present invention in an acyl group having 1 to 7 carbon atoms among (C1-C13) acyl groups represented by R of a compound represented by the above general formula (I) and specifically includes, for example, a formyl group, an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group, a pivaloyl group, a hexanoyl group, a cyclopropylcarbonyl group, a cyclopentylcarbonyl group or a cyclohexanecarbonyl group.
  • the (C1-C7) acyloxy group in the present invention is a group in which a (C1-C7) acyl group mentioned above is linked with an oxygen atom and includes, for example, a formyloxy group, an acetoxy group, a propionyloxy group, a butyryloxy group, an isobutyryloxy group, a valeryloxy group, an isovaleryloxy group, a pivaloyloxy group, a hexanoyloxy group, a cyclopropylcarbonyloxy group, a cyclopentylcarbonyloxy group or a cyclohexanecarbonyloxy group.
  • it is an acetoxy group, a propionyloxy group or a pivaloyloxy group, and preferably it is an acetoxy group.
  • the (C1-C7) acylamino group in the present invention refers to a group in which a (C1-C7) acyl group as mentioned above is linked with a nitrogen atom and includes, for example, a formylamino group, an acetylamino group, a propionylamino group, a butyrylamino group, an isobutyrylamino group, a valerylamino group, an isovalerylamino group, a pivaloylamino group, a hexanoylamino group, a cyclopropylcarbonylamino group, a cyclopentylcarbonylamino group or a cyclohexanecarbonylamino group.
  • it is an acetylamino group, a propionylamino group or a pivaloylamino group, and more preferably it is an acetylamino group.
  • the (C1-C6) alkylsulfanyl group in the present invention refers to a group in which a (C1-C6) alkyl group as mentioned above is linked with a sulfur atom and includes, for example, a methylsulfanyl group, an ethylsulfanyl group, a propylsulfanyl group, an isopropylsulfanyl group, a butylsulfanyl group, an isobutylsulfanyl group, a tert-butylsulfanyl group, a pentylsulfanyl group, an isopentylsulfanyl group, a 2-methylbutylsulfanyl groups, a neopentylsulfanyl group, a 1-ethylpropylsulfanyl group, a hexylsulfanyl group, a 4-methylpentylsulfanyl group, a 3-methylp
  • it is a methylsulfanyl group, an ethylsulfanyl group, a propylsulfanyl group, an isopropylsulfanyl group, a butylsulfanyl group, an isobutylsulfanyl group or a tert-butylsulfanyl group, and more preferably it is a methylsulfanyl group or an ethylsulfanyl group.
  • the arylsulfanyl group in the present invention is preferably a group in which an aromatic hydrocarbon group having 6 to 10 carbon atoms is linked with a sulfur atom and includes, for example, a phenylsulfanyl group, a toluen-2-ylsulfanyl group, a toluen-3-ylsulfanyl group, a toluen-4-ylsulfanyl group, a naphthalen-1-ylsulfanyl group or a naphthalen-2-ylsulfanyl group, and preferably it is a phenylsulfanyl group, a toluen-3-ylsulfanyl group or a toluen-4-ylsulfanyl group, and more preferably it is a phenylsulfanyl group.
  • the (C1-C6) alkylsulfonyl group in the present invention is preferably a group in which a (C1-C6) alkyl group mentioned above is linked with a sulfonyl group and includes, for example, a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, a butylsulfonyl group, an isobutylsulfonyl group, a tert-butylsulfonyl group, a pentylsulfonyl group, an isopentylsulfonyl group, a 2-methylbutylsulfonyl group, a neopentylsulfonyl group, a 1-ethylpropylsulfonyl group, a hexylsulfonyl group, a
  • it is a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, a butylsulfonyl group, an isobutylsulfonyl group or a tert-butylsulfonyl group, and more preferably it is a methylsulfonyl group or an ethylsulfonyl group.
  • the arylsulfonyl group in the present invention is preferably a group in which an aromatic hydrocarbon having a 6 to 10 carbon atoms is linked with a sulfonyl group and includes, for example, a phenylsulfonyl group, a toluen-2-ylsulfonyl group, a toluen-3-ylsulfonyl group, a toluen-4-ylsulfonyl group, a naphthalen-1-ylsulfonyl group or a naphthalen-2-ylsulfonyl group.
  • it is a phenylsulfonyl group, a toluen-3-ylsulfonyl group or a toluen-4-ylsulfonyl group, and more preferably it is a phenylsulfonyl group.
  • the (C1-C6) alkylamino group in the present invention is a group in which one (C1-C6) alkyl group mentioned above is linked with a nitrogen atom and includes, for example, a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group, an isobutylamino group, a tert-butylamino group, a pentylamino group, an isopentylamino group, a 2-methylbutylamino group, a neopentylamino group, a 1-ethylpropylamino group, a hexylamino group, a 4-methylpentylamino group, a 3-methylpentylamino group, a 2-methylpentylamino group, a 1-methylpentylamino group, a 3,3-dimethylbutylamino group, a
  • it is a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group, an isobutylamino group or a tert-butylamino group, and more preferably it is a methylamino group or an ethylamino group.
  • the di(C1-C6) alkylamino group in the present invention is a group in which two identical (C1-C6) alkyl groups mentioned above are linked with a nitrogen atom and includes, for example, a dimethylamino group, a diethylamino group, a dipropylamino group, a diisopropylamino group, a dibutylamino group, a diisobutylamino group, a dipentylamino group, a dihexylamino group, a bis(3,3-dimethylbutyl)amino group, a dicyclopropylamino group, a dicyclopentylamino group or a dicyclohexylamino group.
  • it is a dimethylamino group, a diethylamino group, a dipropylamino group, a diisopropylamino group, a dibutylamino group or a diisobutylamino group, and more preferably it is a dimethylamino group or a diethylamino group.
  • the (C2-C7) alkoxycarbonylamino group in the present invention is a group in which a (C2-C7) alkoxycarbonyl group mentioned above is linked with a nitrogen atom and includes, for example, a methoxycarbonylamino group, an ethoxycarbonylamino group, a propoxycarbonylamino group, an isopropoxycarbonylamino group, a butoxycarbonylamino group, an isobutoxycarbonylamino group, a tert-butoxycarbonylamino group, a pentyloxycarbonylamino group, an isopentyloxycarbonylamino group, a 2-methylbutoxycarbonylamino group, a neopentyloxycarbonylamino group, a 1-ethylpropoxycarbonylamino group, a hexyloxycarbonylamino group, a 4-methylpentyloxycarbonylamino group, a 3-methylpentyloxy
  • it is a methoxycarbonylamino group, an ethoxycarbonylamino group, a propoxycarbonylamino group, an isopropoxycarbonylamino group, a butoxycarbonylamino group, an isobutoxycarbonylamino group or a tert-butoxycarbonylamino group, and more preferably it is an ethoxycarbonylamino group, a tert-butoxycarbonylamino group.
  • the 5- or 6-membered aromatic heterocyclic group which contains which contains 1 to 4 hetero atoms independently selected from N, O and S as a substituent in R of a compound represented by general formula (I) in the drug of the present invention preferably includes, for example, saturated heterocyclic groups such as a tetrahydrofuran-2-yl group, a tetrahydropyran-2-yl group, a tetrahydropyran-4-yl group, a [1,3]dioxolan-2-yl group, a [1,3]dioxan-2-yl group, a pyrrolidin-1-yl group, a piperidin-1-yl group, a piperidin-4-yl group, an azepan-1-yl group, a morpholin-4-yl group, a thiomorpholin-4-yl group, an oxazolidin-3-yl group, an isoxazolidin-2-yl group, a thiazo
  • the above heterocyclic group in a substituent in the case where R is a (C1-C13) aliphatic acyl group in general formula (I) is more preferably a tetrahydrofuran-2-yl group, a tetrahydropyran-4-yl group, a furan-2-yl group, a furan-3-yl group, a thiophen-2-yl group, a thiophen-3-yl group, a pyridin-2-yl group, a pyridin-3-yl group or a pyridin-4-yl group, and a furan-2-yl group, a thiophen-2-yl group or a pyridin-3-yl group is particularly preferable.
  • the above heterocyclic group in Z in the case where R is a cyclic acyl group Z-CO- in general formula (I) is more preferably unsaturated heterocyclic groups such as a furan-2-yl group, a furan-3-yl group, a dihydropyran-2-yl group, a thiophen-2-yl group, a thiophen-3-yl group, a pyrrol-2-yl group, a pyridin-2-yl group, a pyridin-3-yl group, a pyridin-4-yl group, a pyrimidin-4-yl group or a pyrazin-2-yl group and a furan-2-yl group, a dihydropyran-2-yl group, a thiophen-2-yl group, a pyrrol-2-yl group or a pyridin-3-yl group is particularly preferable.
  • Ar in a compound represented by general formula (I) in the drug of the present invention includes, for example, a phenyl group, a 3-fluorophenyl group, a 3-chlorophenyl group, a 3-hydroxyphenyl group, a 3-cyanophenyl group, a 3-nitrophenyl group, a 3-methylphenyl group, a 3-ethylphenyl group, a 3-propylphenyl group, a 3-isopropylphenyl group, a 3-butylphenyl group, a 3-methoxyphenyl group, a 3-ethoxyphenyl group, a 3-isopropoxyphenyl group, a 3-isobutoxyphenyl group, a 3-aminophenyl group, a 3-acetylaminophenyl group, a 3-propionylaminophenyl group, a 4-fluorophenyl group, a 4-chlorophenyl group, a 4-hydroxyphenyl group,
  • R in a compound represented by general formula (I) in the drug of the present invention are preferably a methyl group, an ethyl group, a tert-butoxycarbonyl group, an acetyl group, a benzoyl group, a 4-chloro-2-methoxybenzoyl group, a furan-2-ylcarbonyl group, a 3-(phenylsulfonyl)propionyl group, an (S)-2-aminopropionyl group, an (S)-2-aminobutyryl group, an (S)-2-amino-3-methylbutyryl group, an (S)-2-(tert-butoxycarbonyl)aminopropionyl group, an (S)-2-(tert-butoxycarbonyl)aminobutyryl group or an (S)-2-(tert-butoxycarbonyl)amino-3-methylbutyryl group, and preferably a 3-(phenylsulfonyl group
  • specific compounds of substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives represented by general formula (I) in a drug of the present invention correspond to compounds derived by combining specific examples of Ar and R mentioned above.
  • each isomer and a mixture thereof are included in the present invention. That is, in the case of optical isomer, racemic compound, each enantiomer and a mixture thereof in any ratio are also included in the present invention.
  • Such optical isomers are prepared by a conventional production process, that is, synthesis using optical active raw materials or optical resolution method or separation method of the synthesized compounds.
  • Preferable substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative represented by general formula (I) in a drug of the present invention are compounds shown in Table 6 below and 3-benzenesulfonyl-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propionamide, 3-benzenesulfonyl-N-(7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propionamide, (S)-2-(tert-butoxycarbonyl)amino-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]butylamide, (S)-2-amino-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)
  • the pharmaceutically acceptable salt of a [1,2,4]triazolo[1,5-a]pyrimidine derivative of the present invention is prepared by salification operation of a conventional method and, for example, alkali metal salts such as sodium, potassium salt, lithium salt; alkaline earth metal salts such as calcium salt, magnesium salt; other metal salts such as aluminum salt, iron salt, zinc salt; ammonium salt and so on; organic amine salts such as morpholine salt, ethylenediamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, procaine salt, diethanolamine salt, piperazine salt, tetramethylammonium salt; hydrohalic acid salts such as hydrofluoric acid salt, hydrochloride, hydrobromic acid salt, hydroiodic acid salt; inorganic acid salts such as nitrate, perchlorate, sulfate, phosphate; organic sulfonic acid salts such as methanesul
  • Prodrugs which generate a drug of the present invention under physiological condition (physiological condition which, for example, is described in pp. 163-198 in "development of a drug", Vol. 7 "Molecular design", Hirokawa Shoten, 1990) in a living body, for example, by oxidation reaction, reductive reaction, hydrolysis reaction and so on with an enzyme or a gastric acid are included in the present invention.
  • Examples of prodrug include an acylated compound, alkylated compound, phosphorylated compound of the active compound which it can be produced by a conventional organic reaction.
  • solvates such as hydrate of 2-amino[1,2,4]triazolo[1,5-a]pyrimidine derivatives are included in the present invention entirely.
  • An antigen presentation inhibitor which comprises as an active ingredient a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative represented by the above general formula (I) which is used as a drug of the present invention and has antigen presentation inhibitory activity as shown in the following test examples or pharmaceutically acceptable salt thereof is also included in the present invention.
  • an immunosuppresant which comprises as an active ingredient the substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or pharmaceutically acceptable salt thereof is also included in the present invention.
  • a lymphocyte proliferation inhibitor, cell differentiation/maturation inhibitor, immunotolerance inducer which comprises as an active ingredient the substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative or pharmaceutically acceptable salt thereof is also included in the present invention, and further, a therapeutic agent or a prophylactic agent for transplant rejection reaction or graft versus host reaction disease, a therapeutic agent or a prophylactic agent for autoimmune diseases, a therapeutic agent or a prophylactic agent for allergic diseases, a therapeutic agent or a prophylactic agent for inflammatory diseases, an antineoplastic drug are included in the present invention.
  • the antigen presentation inhibitory substance of the present invention can be used for a therapeutic agent or a prophylactic agent for acute rejection reaction in transplantation, graft-versus-host disease, chronic rejection reaction, induction of immune tolerance, etc.
  • the transplant may be any organ such as bone marrow, kidney, liver, heart and pancreas.
  • any case including xenograft transplantation, allograft transplantation, transplantation with blood incompatibility is possible. It can be used for the purpose of immune inhibition and long-term survival of the transplanted organ in organ transplantation such as bone marrow transplantation, peripheral blood stem cell transplantation and umbilical cord blood stem cell transplantation used for cancer therapy, treatment of autoimmune diseases, gene therapy and regeneration medicine.
  • the therapeutic agent or prophylactic agent for autoimmune diseases specifically includes a therapeutic agent or prophylactic agent for rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, discoid lupus erythematosus, Sjogren's syndrome, Crohn's disease, colitis ulcerosa, idiopathic thrombocytopenia, aplastic anemia, autoimme hepatitis, insulin-dependent diabetes, myasthenia gravis, polymyositis, scleroderma, mixed connective tissue disease, ankylosing spondylitis or chronic thyroiditis.
  • the therapeutic agent or prophylactic agent for allergic diseases specifically includes a therapeutic agent or prophylactic agent for atopic dermatosis, pollinosis, contact hypersensitivity, asthma, psoriasis or anaphylaxis.
  • the therapeutic agent or prophylactic agent for inflammatory diseases specifically includes a therapeutic agent or prophylactic agent for Behcet's disease, polyarteritis, sarcoidosis, glomerulonephritis, nephrotic syndrome, intractable vasculitis or Wegener's syndrome.
  • the antineoplastic drug includes a therapeutic agent for malignant tumor such as lymphomas, leukemia, brain tumor, lung cancer, pancreas cancer, gastric cancer, large bowel cancer.
  • the drug of the present invention can be administered as it is or as a pharmaceutical composition mixed with a pharmaceutical acceptable carrier.
  • the drug form of the pharmaceutical composition may be any type. These preparations may contain other ingredients valuable for the treatment.
  • the ratio of the active ingredient of the present invention in the preparation is 1 to 100 %, preferably around 10 to 90%by weight for the whole preparation.
  • the drug of the present invention may be administered in any manner comprising oral administration, injection, intrarectal administration, intraportal administration, visceral perfusion, local administration to an organ.
  • the dosage of the drug of the present invention may vary dependent on administration method, applicable disease, pathological conditions age, body weight of a patient, but a usual dose is 0.01 mg to 500 mg/kg, preferably 0.05 mg to 50 mg/kg, which may be administered once a day or divided into several times a day.
  • the administration can be performed one day alone or day after day, and repetitive administration may be performed with an interval of several days to several months.
  • the administration method, dosage and administration schedule other than the above can be used as required.
  • the [1,2,4]triazolo[1,5-a]pyrimidine derivative represented by general formula (I) in the present invention can be obtained, for example, by the method shown in the following Formula C in the case where R is an alkyl group, can be obtained, for example, by the method shown in the following Formula A or B in the case where R is an alkoxycarbonyl group, an aliphatic acyl group, an amino acid group or a cyclic acyl group.
  • Ar represents the meaning same as the above.
  • the compound in the reaction may form a salt which includes, for example, those similar to the salt of the [1,2,4]triazolo[1,5-a]pyrimidine derivatives represented by above general formula (I) (hereinafter compound (I)).
  • E represents a residue of a (C2-C7) alkoxycarbonyl group in which ECO may be substituted with a substituent, (C1-C13) aliphatic acyl group which may have 1 to 3 same or different substituents, an amino acid group in which N-terminal may by protected or a 3- to 7-membered cyclic acyl group which may have 1 to 3 same or different substituents, and L represents a leaving group.
  • the leaving group includes, for example, a halogeno group, a 4-nitrophenoxy group, a pentafluorophenoxy group, a pyridin-2-ylsulfanyl group, an imidazol-1-yl group, a alkoxycarbonyl group, and preferably it is a halogeno group.
  • the base includes, for example, alkali metal carbonates such as lithium carbonate, sodium carbonate and potassium carbonate, alkaline metal bicarbonates such as lithium hydrogen carbonate, sodium hydrogen carbonate and potassium bicarbonate, alkali metal hydrides such as lithium hydride, sodium hydride and potassium hydride, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide, alkali metal alkoxides such as lithium methoxide, sodium methoxide, sodium ethoxide and potassium tert-butoxide, alkyl metals such as butyllithium and tert-butylmagnesium chloride, metal amides such as lithium diisopropylamide (LDA), lithium bis(trimethylsilyl)amide and sodium bis(trimethylsilyl)amide
  • the amount of the base to be used is 0.5 to 5 mol equivalent, preferably 1 to 2 mol equivalent for compound (a).
  • the amount of compound (b) to be used is 0.5 to 5 mol equivalent, preferably 1 to 2 mol equivalent for compound (a).
  • a catalyst such as 4-(N, N-dimethylamino) pyridine in catalytic amount may be added if necessary.
  • the reaction is performed in the absence of or in the presence of a solvent and preferably it is performed in the presence of a solvent.
  • the solvent is not particularly limited as far as the reaction proceeds and includes, for example, aliphatic hydrocarbons such as hexane, heptane, ligroin and petroleum ether, aromatic hydrocarbons such as benzene, toluene, xylene, halogenated hydrocarbons such as methylene chloride, chloroform and 1,2-dichloroethane, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, diethylene glycol dimethyl ether, nitriles such as acetonitrile and propionitrile, amides such as dimethylformamide, dimethylacetamide and hexamethylphosphoric triamide, ureas such as 1,3-dimethylimidazolidin-2-one or a mixture
  • compound (a) or compound (b) has a reactive group such as a hydroxyl group or an amino group
  • this reaction is preferably performed while protecting with a protecting group which is used in a conventional reaction.
  • compound (b) is commercially available, the commercial article may be just used or the compound may be prepared according to a known method or a method following the same.
  • the compound can be derived from a compound in which L is a hydroxyl group.
  • the fluorination reagent to be used includes, for example, cyanuric fluoride, TFFH (tetramethylfluoroformamidinium hexafluorophosphate), DAST ((dimethylamino) sulfur trifluoride) and preferably it is TFFH.
  • the amount of the fluorination reagent to be used is 0.5 to 5 mol equivalent, preferably 1 to 2 mol equivalent for the compound in which L is a hydroxyl group.
  • the fluorination reaction is performed in the absence of or in the presence of a base and preferably it is performed in the presence of a base.
  • the base includes, for example, organic amines and the like such as triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4-(N,N-dimethylamino)pyridine, N,N-dimethylaniline, N,N-diethylaniline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]-7-undecene (DBU), and preferably it is diisopropylethylamine or pyridine.
  • the amount of the base to be used is 0.5 to 5 mol equivalent, preferably 1 to 2 mol equivalent for the compound in which L is a hydroxyl group.
  • the fluorination reaction is performed in the absence of or in the presence of a solvent, and preferably it is performed in the presence of a solvent.
  • the solvent is not particularly limited as far as the reaction proceeds and includes, for example, aliphatic hydrocarbons such as hexane, heptane, ligroin and petroleum ether, aromatic hydrocarbons such as benzene, toluene, xylene, halogenated hydrocarbons such as methylene chloride, chloroform and 1,2-dichloroethane, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, diethylene glycol dimethyl ether, nitriles such as acetonitrile and propionitrile, amides such as dimethylformamide, dimethylacetamide and hexamethylphosphoric triamide, ureas such as 1,3-dimethylimidazolidin-2-
  • the reaction temperature is usually -80 to 150°C, preferably 10 to 50°C.
  • the reaction time is usually from 10 minutes to 12 hours.
  • the commercial article may be just used or the compound may be prepared according to a known method or a method following the same.
  • the compound obtained in the fluorination reaction may be isolated according to a conventional method, but may be used for the next reaction as a reaction liquid without isolating it.
  • reaction with the above compound (a) is performed particularly preferably in the presence of 1 to 2 equivalent amount of an alkali metal hydride or a metal amide in tetrahydrofuran or 1,3-dimethylimidazolidin-2-one at a reaction temperature of -10 to 50°C as a reaction condition.
  • the compound when L of the above compound (b) is a chlorine atom, the compound can be derived from a compound in which L is a hydroxyl group.
  • the chlorination reagent to be used includes, for example, thionyl chloride, oxalyl chloride, cyanuric chloride, and preferably it is oxalyl chloride.
  • the chloridization reaction is performed under the condition similar to that of the fluorination reaction mentioned above, and preferable reaction condition is the same.
  • a production process in which compound (c) is converted into acid anhydride (d) by a dehydration condensation agent and it is reacted with compound (a), and thereby obtaining a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative (I') is described.
  • Usable dehydration condensation agent includes, for example, dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-dimethylaminopropyl-3-ethylcarbodiimide, and preferably it is diisopropylcarbodiimide.
  • the amount of the dehydration condensation agent to be used is 0.3 to 0.8 mol equivalent, preferably 0.5 mol equivalent for compound (c).
  • the dehydration condensation reaction is performed in the absence of or in the presence of a solvent, and preferably it is performed in the presence of a solvent.
  • the solvent is not particularly limited as far as the reaction proceeds and includes, for example, aliphatic hydrocarbons such as hexane, heptane, ligroin and petroleum ether, aromatic hydrocarbons such as benzene, toluene, xylene, halogenated hydrocarbons such as methylene chloride, chloroform and 1,2-dichloroethane, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, diethylene glycol dimethyl ether, nitriles such as acetonitrile and propionitrile, ureas such as 1,3-dimethylimidazolidin-2-one or a mixture of the above solvents, and preferably it is a halogenated hydrocarbon, an
  • the reaction temperature is usually -20 to 100°C, preferably -10 to 50°C.
  • the reaction time is usually from several minutes to 12 hours.
  • the commercial article may be just used or the compound may be prepared according to a known method or a method following the same.
  • the compound obtained in the dehydration condensation reaction may be isolated according to a conventional method, but may be used for the next reaction as a reaction solution without isolating it.
  • the amount of acid anhydride (d) to be used in the reaction of compound (a) with the acid anhydride (d) obtained by the above method is 0.5 to 4 mol equivalent, preferably 1.0 to 3.0 mol equivalent for compound (a).
  • This reaction is performed in the absence of or in the presence of a solvent, and preferably it is performed in the presence of a solvent.
  • a solvent those solvents shown in the above Formula A can be used.
  • the reaction temperature is usually from room temperature to 150°C and preferably 80 to 120°C.
  • the reaction time is usually 1 to 12 hours.
  • compound (a) or compound (c) has a reactive group such as a hydroxyl group or an amino group, this reaction is preferably performed while protecting with a protecting group.
  • D represents a (C1-C6) alkyl group which may have a substituent
  • L' represents a leaving group
  • Y represents a (C1-C6) alkyl group which may have a substituent.
  • the leaving group includes, for example, a chloro group, a bromo group, a iodo group, a methane sulfonyloxy group, a p-toluenesulfonyl group.
  • compound (I"') is obtained by dealkoxycarbonylation reaction.
  • the first step reaction is usually performed in the presence of a base, and the base includes, for example, alkali metal carbonates such as lithium carbonate, sodium carbonate and potassium carbonate, alkaline metal bicarbonates such as lithium hydrogen carbonate, sodium hydrogen carbonate and potassium bicarbonate, alkali metal hydrides such as lithium hydride, sodium hydride and potassium hydride, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide, alkali metal alkoxides such as lithium methoxide, sodium methoxide, sodium ethoxide and potassium tert-butoxide, alkyl metals such as butyllithium and tert-butylmagnesium chloride, metal amides such as lithium diisopropylamide (LDA), lithium bis(trimethylsilyl
  • LDA lithium diisopropylamide
  • the amount of the base to be used is 0.5 to 5 mol equivalent, preferably 1 to 2 mol equivalent for compound (I").
  • the amount of compound (e) to be used is 0.5 to 5 mol equivalent, preferably 1 to 2 mol equivalent for compound (I").
  • This reaction is performed in the absence of or in the presence of a solvent, and preferably it is performed in the presence of a solvent.
  • the solvent is not particularly limited as far as the reaction proceeds and includes, for example, aliphatic hydrocarbons such as hexane, heptane, ligroin and petroleum ether, aromatic hydrocarbons such as benzene, toluene, xylene, halogenated hydrocarbons such as methylene chloride, chloroform and 1,2-dichloroethane, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, diethylene glycol dimethyl ether, nitriles such as acetonitrile and propionitrile, amides such as dimethylformamide, dimethylacetamide and hexamethylphosphoric triamide, ureas such as 1,3-dimethylimidazolidin-2-one or a
  • the reaction temperature is usually -80 to 150°C, preferably 0 to 80°C.
  • the reaction time is usually from 10 minutes to 48 hours.
  • compound (I") has a reactive group such as a hydroxyl group or an amino group, this reaction is preferably performed while protecting with a protecting group.
  • compound (e) is commercially available, the commercial article may be just used or the compound may be prepared according to a known method or a method following the same.
  • the second step reaction is performed under a condition of conventional de-alkoxycarbonylation reaction.
  • Y in this reaction preferably includes, for example, a tert-butyl group or a benzyl group, and when it is tert-butyl group, the reaction is performed with an acid such as trifluoroacetic acid and hydrochloric acid and when x is a benzyl group, the reaction is performed by reduction reaction under hydrogen atmosphere with palladium carbon and the like.
  • Compound (a) used in the above Formula A or B can be obtained by a process described in the following Formula D which follows a known method for producing a [1,2,4]triazolo[1,5-a]pyrimidine derivative, for example, those described in JP-A-04-099775, US Patent No.4,444,774, Reiter, J. et al., Tetrahedron, vol. 43, 2497-2504 (1987).
  • Acetophenones (k) and a formamide dimethylacetal compound are condensed to obtain compound (m).
  • the amount of formamide dimethylacetal compound to be used is 0.5 to 5 mol equivalent, preferably 1 to 3 mol equivalent for compound (k). This reaction is performed in the absence of or in the presence of a solvent.
  • the solvent is not particularly limited as far as the reaction proceeds and includes, for example, aliphatic hydrocarbons such as hexane, heptane, ligroin and petroleum ether, aromatic hydrocarbons such as benzene, toluene, xylene, halogenated hydrocarbons such as methylene chloride, chloroform and 1,2-dichloroethane, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, diethylene glycol dimethyl ether, or a mixture of the above solvents, and preferably it is an aromatic hydrocarbons such as benzene, toluene, xylene.
  • aromatic hydrocarbons such as benzene, toluene, xylene
  • halogenated hydrocarbons such as methylene chloride, chloroform and 1,2-dichloroethane
  • ethers such as diethy
  • the reaction temperature is usually 80 to 200°C, preferably 110 to 150°C.
  • the reaction time is usually from 6 to 48 hours.
  • compound (k) and a formamide dimethylacetal compound when they are commercially available, the commercial articles may be just used or the compounds may be prepared according to a known method or a method following the same.
  • compound (m) and 3,5-diamino-1,2,4-triazole are condensed to obtain compound (a).
  • the acid includes, for example, mineral acids such as hydrochloric acid and sulfuric acid, carboxylic acids such as acetic acid, benzoic acid and trifluoroacetic acid, sulfonic acids such as methanesulfonic acid, trifluoromethane sulfonic acid, p-toluenesulfonic acid and camphor sulfonic acid, Lewis acids such as boron trifluoride, titanium tetrachloride and stannic tetrachloride, and preferably it is a sulfonic acid.
  • the amount of the acid to be used is 0.1 mol equivalent to large excess, preferably 0.2 to 2 mol equivalent for compound (m).
  • the amount of 3,5-diamino-1,2,4-triazole to be used is 0.5 to 10 mol equivalent, preferably 1 to 4 mol equivalent for compound (m).
  • This reaction is performed in the absence of or in the presence of a solvent, and the solvent is not particularly limited as far as the reaction proceeds and includes, for example, aliphatic hydrocarbons such as hexane, heptane, ligroin and petroleum ether, aromatic hydrocarbons such as benzene, toluene, xylene, halogenated hydrocarbons such as methylene chloride, chloroform and 1,2-dichloroethane, ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, diethylene glycol dimethyl ether, nitriles such as acetonitrile and propionitrile, amides such as dimethylformamide, dimethylacetamide and hexamethylphosphoric triamide, ureas such as 1,3-dimethylimidazolidin-2-one, carboxylic acids such as acetic acid and propionic acid or
  • substituents on Ar and R in a compound represented by general formula (I) can be produced by converting according to a conventional method or a method following the same, as required, for example, by reaction such as esterification reaction, amidation reaction, hydrolysis reaction, oxidation reaction, reductive reaction, alkylation reaction, conventional deprotection reaction or the like.
  • a protecting group when a reactive group such as an amino group and a hydroxyl group is included in a substituent in the above reaction known methods (for example, a method described in Greene, T.W. et al., "PROTECTIVE GROUPS IN ORGANIC SYNTHESIS", second edition, WILEY INTERSCIENCE (U.S.A.)) can be used.
  • the protecting group of an amino group includes, for example, a (C1-C7) acyl group, a benzoyl group, a (C2-C7) alkoxycarbonyl group, a benzyloxycarbonyl group, a phthaloyl group.
  • the protecting group of a hydroxyl group includes, for example, a (C1-C6) alkyl group, a benzyl group, a (C1-C7) acyl group, a benzoyl group, an alkylsubstituted silyl group.
  • Each product in each of the above processes can be isolated and purified according to known separation means, for example, by distillation, vacuum concentration, solvent extraction, crystallization and chromatography.
  • the present invention also includes a substituted 2-amino[1,2,4]triazolo[1,5-a]pyrimidine derivative represented by the above-mentioned general formula (III) wherein A represents a phenyl group which may be substituted with 1 to 3 same or different substituents selected from the substituent group (A) consisting of a halogeno group, a hydroxyl group, a (C1-C6) alkyl group, a cyano group, a nitro group, a (C1-C6) alkoxyl group, a benzyloxy group, an amino group, a (C1-C7) acylamino group and a methylenedioxy group or a 5- or 6-membered aromatic heterocyclic group which contains one hetero atom and may be substituted with 1 to 3 same or different substituents selected from the substituent group (A); W represents a (C1-C6) alkyl group which may be substituted with one substituent selected from the substituent group consisting of a
  • Preferable compounds as a substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative of the present invention include 3-benzenesulfonyl-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propionamide, 3-benzenesulfonyl-N-(7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propionamide, (S)-2-(tert-butoxycarbonyl)amino-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)butylamide, (S)-2-amino-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)butylamide or (
  • Test Example 1 Effect on MHC class I expression of T1 cell (Human lymphoma line 174 ⁇ CEM.) T1 cells (5.7 ⁇ 10 3 cells/200 ⁇ L/well) were incubated using a 96-well flat bottom microplate in RPMI1640 culture medium (Iwaki Glass Corporation) containing 10% bovine serum (hereinafter referred to as FBS; Iruvine Scientific) in the presence of a test compound of each concentration diluted from 400 ⁇ M by a common ratio of root 10 at 37°C in an incubator containing 5% carbon dioxide concentration for three days.
  • FBS bovine serum
  • MFI mean fluorescence intensity
  • Test Compound Example Number EC 20 ( ⁇ M) Test Compound Example Number EC 20 ( ⁇ M) 001 6.0 026 8.8 007 6.25 028 7.7 008 7.5 036 7.1 009 7.2 040 8.4 013 8.2 047 7.3 015 9.2 052 6.8 016 9.7 054 4.0 020 5.3 055 1.6 022 8.2 056 0.74 It was shown from these results that the compounds of the present invention inhibited MHC class I expression of T1 cells.
  • Test Example 2 Effect on MHC class I expression of dendritic cell derived from human peripheral blood Mononuclear leukocytes were separated from human peripheral blood by specific gravity centrifugal method and CD14 positive cells were separated the peripheral blood mononuclear leukocytes using mouse antihuman CD14 antibody binding microbeads and a magnetic cell separation system (Miltenyi Biotec GmbH). The separated CD14 positive cells were floated in RPMI1640 culture medium containing 10% FBS, and disseminated on a 6-well plate to attain 1.0 ⁇ 10 6 cells/ well and incubated at 37°C in an incubator containing 5% carbon dioxide concentration for 20 minutes. After incubation, non-adherent cells which did not have adhesive property and floated in the solution were removed.
  • GM-CSF human recombinant granulocyte colony-stimulating factor
  • IL-4 human recombinant interleukin 4
  • 2 mL/well of RPMI1640 containing 10% FBS 2 mL/well of RPMI1640 containing 10% FBS and incubated at 37°C in an incubator containing 5% carbon dioxide concentration.
  • immature dendritic cells were obtained by collecting non-adhesive cells.
  • the immature dendritic cells (2 ⁇ 10 5 cells/well) were incubated using a 6-well plate in RPMI1640 culture medium containing 10% FBS to which 100 U/mL of human recombinant tumor necrosis factor- ⁇ (hereinafter referred to as TNF- ⁇ ; PeproTech) and a test compound were added at 37°C in an incubator containing 5% carbon dioxide concentration for three days.
  • TNF- ⁇ tumor necrosis factor- ⁇
  • PeproTech tumor necrosis factor- ⁇
  • the dendritic cells matured by TNF- ⁇ but a test compound was acted on them in this test at the same time.
  • Test Compound EC 20 Example Number ( ⁇ M) 055 6.7 056 6.3 It was shown that the compounds of the present invention inhibited MHC class I expression of dendritic cells derived from human peripheral blood.
  • Test Example 3 Effect on ability of human dendritic cell inducing proliferation of allogeneic T cell Immature dendritic cells were incubated with a test compound and TNF- ⁇ for three days in the same manner as in the method described in Test Example 2.
  • the obtained dendritic cells (2.5 ⁇ 10 3 cells/50 ⁇ L/well) were incubated using a 96-well flat bottom plate in a mixed condition with human allogeneic T cells (2.0 ⁇ 10 6 cells/150 ⁇ L/well) at 37°C in an incubator containing 5% carbon dioxide concentration for five days.
  • 1 ⁇ Ci/10 ⁇ L/ well of [ 3 H]-thymidine was added 16 hours before culture termination.
  • Test Compound EC 20 Example Number ( ⁇ M) 028 24.1 044 27.5 It was shown that the compounds of the present invention inhibited the ability of dendritic cell to induce proliferation of lymphocyte.
  • Test Example 4 Cytotoxic effect on T1 cell (Human lymphoma line 174 ⁇ CEM.) T1 cells (5.7 ⁇ 10 3 cells/200 ⁇ L/well) were incubated using a 96-well flat bottom microplate in RPMI1640 culture medium containing 1.0% FBS in the presence of a test compound of each concentration diluted from 400 ⁇ M by a common ratio of root 10 at 37°C in an incubator containing 5% carbon dioxide concentration for three days. After incubation, damaged cells were stained with propodium iodide. IC 50 values were determined from the stained number to all number measured with flow cytometry FACScan (BD), and this was assumed as cytotoxic activity. The results are shown in Table 4.
  • Test Compound EC 20 Example Number ( ⁇ M) 029 1.3 030 14.1 051 3.2 It was shown that the compounds of the present invention have ytotoxic effect on T1 cells and anti cell proliferation inhibition activity.
  • Reference Example 002 Synthesis of 7-(4-nitrophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine 4'-nitroacetophenone was used in place of 2-acetylthiophene in Reference Example 001 and heated to reflux in xylene in the presence of N,N-dimethylformamide diethyl acetal as in Reference Example 001, and 3-dimethylamino-1-(4-nitrophenyl)propenone (quantitative) was obtained, which was subsequently reacted with 3,5-diamino-1,2,4-triazole in xylene in the presence of 10-camphor sulfonic acid and the title compound was obtained (yield 82%).
  • Reference Example 003 Synthesis of 7-(4-nitrophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine 7-(4-aminophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine (62.0 mg) obtained in Reference Example 002 was suspended in acetic acid (0.8 mL) and stirred at room temperature overnight with tin (II) chloride dihydrate (200 mg) and concentrated hydrochloric acid (0.6 mL) added. The reaction liquid was neutralized with 6M aqueous sodium hydroxide solution and the sedimented deposit was separated by filtration. It was suspended and washed with distilled water, ethanol and methylene chloride in this order and the title compound was obtained (42.3 mg, yield 77%).
  • Reference Example 004 Synthesis of 7-(4-aminophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine 7-(4-nitrophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine (20.1 mg)obtained in Reference Example 003 was suspended in methanol (2 mL) and stirred for all one day with acetic acid anhydride (16. 9 ⁇ L) added. After 5% potassium carbonate aqueous solution (5 mL) was added to the reaction liquid, which was subjected to centrifugal separation (2000rpm, 10 minutes). The supernatant was removed and the precipitation was suspended and washed with ethanol and methylene chloride in this order and the title compound was obtained (19.2 mg, yield 81%).
  • Reference Example 005 Synthesis of 7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidylamine 4'-methoxy acetophenone was used in place of 2-acetylthiophene in Reference Example 001 and heated to reflux in xylene in the presence of N,N-dimethylformamide diethyl acetal as in Reference Example 001, and 3-dimethylamino-1-(4-methoxyphenyl)propenone (yield 99%) was obtained, which was subsequently reacted with 3,5-diamino-1,2,4-triazole in toluene in the presence of 10-camphor sulfonic acid and the title compound was obtained (yield 61%).
  • Reference Example 006 Synthesis of 7-(3-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine 3'-chloroacetophenone was used in place of 2-acetylthiophene in Reference Example 001 and heated to reflux in xylene in the presence of N,N-dimethylformamide diethyl acetal as in Reference Example 001, and 3-dimethylamino-1-(3-chlorophenyl)propenone (quantitative) was obtained, which was subsequently reacted with 3,5-diamino-1,2,4-triazole in toluene in the presence of 10-camphor sulfonic acid and the title compound was obtained (yield 44%).
  • Reference Example 007 Synthesis of 7-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine Acetophenone was used in place of 2-acetylthiophene in Reference Example 001 and heated to reflux in xylene in the presence of N,N-dimethylformamide diethyl acetal as in Reference Example 001, and 3-dimethylamino-1-phenylpropenone (yield 41%) was obtained, which was subsequently reacted with 3,5-diamino-1,2,4-triazole in toluene in the presence of 10-camphor sulfonic acid and the title compound was obtained (yield 63%).
  • Reference Example 008 Synthesis of 7-(3-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine 3'-methoxyacetophenone was used in place of 2-acetylthiophene in Reference Example 001 and heated to reflux in xylene in the presence of N,N-dimethylformamide diethyl acetal as in Reference Example 001, and 3-dimethylamino-1-(3-methoxyphenyl)propenone (quantitative) was obtained, which was subsequently reacted with 3,5-diamino-1,2,4-triazole in toluene in the presence of 10-camphor sulfonic acid and the title compound was obtained (yield 65%).
  • the structural formulas and physicochemical data of the compounds of Reference Examples 001-008 are shown in Table 5 below.
  • Example 001 Synthesis of N-methyl-7-thiophene-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylamine
  • the compound of Example 005 (69.4 mg, 0.22 mmol) was dissolved in N,N-dimethylformamide (1.6 mL) and stirred at room temperature for one hour with sodium hydride (60% paraffin solution, 17.6 mg, 0.44mmol) and methyl iodide (27.4 ⁇ L, 0.44 mmol) added. After diluted with methylene chloride (5 mL), the mixture was washed with 0.4M hydrochloric acid water and distilled water.
  • Example 005 Synthesis of 7-thiophene[1,2,4]triazolo[1,5-a]pyrimidin-2-ylcarbamic acid tert-butyl ester (example of Reaction Formula A)
  • the compound of Reference Example 001 (234 mg, 1.08 mmol) was suspended in tetrahydrofuran (12 mL) and stirred at room temperature for 10 minutes with di-tert-butyldicarbonate (306 mg, 1.40 mmol) and hexamethyldisilazane lithium salt (1M tetrahydrofuran solution, 2 mL) added.
  • Example 022 Synthesis of 3-benzenesulfonyl-N-(7-thiophene[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propionamide (example of Reaction Formula A) 3-(phenylsulfonyl)propionic acid (26.3 mg, 0.12 mmol) was dissolved in tetrahydrofuran (1 mL) and stirred at room temperature for one hour with oxalyl chloride (10.5 ⁇ L, 0.12 mmol) added.
  • Example 028 Synthesis of 6,6-dimethyl-4-oxo-5,6-dihydro-4H-pyran-2-carboxylic acid N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)amide (example of Reaction Formula A) 6,6-dimethyl-4-oxo-5,6-dihydro-4H-pyran-2-carboxylic acid (20.5 mg, 0.12 mmol) was dissolved in tetrahydrofuran (1 mL) and stirred at room temperature for one hour with oxalyl chloride (10.5 ⁇ L, 0.12 mmol) added.
  • Example 035 Synthesis of (2S)-2-methyl-1-(7-thiophen-2-yl-[1,2,4]tri-azolo[1,5-a]pyrimidin-2-ylcarbamoyl)propyl carbamic acid tert-butyl ester (example of Reaction Formula A) N-(tert-butoxycarbonyl)-L-valine (21.7 mg, 0.10 mmol) and TFFH (25.0mg, 0.10 mmol) were dissolve in tetrahydrofuran (1 mL), added with N,N-diisopropylethylamine (34.8 ⁇ L, 0.20 mmol) and stirred at room temperature for one hour to prepared an acid fluoride.
  • (2S)-2-methyl-1-(7-thiophen-2-yl-[1,2,4]tri-azolo[1,5-a]pyrimidin-2-ylcarbamoyl)propyl carbamic acid tert-butyl ester (ex
  • Example 040 Synthesis of ((S)-2-amino-3-methyl-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)butylamide To the compound (13.0 mg, 0. 031 mmol) of Example 035, anisole (50 ⁇ L) and trifluoroacetic acid (1 mL) were added and stirred at room temperature for 40 minutes. Methanol (1. 5 mL) was added to the reaction liquid and the mixture was concentrated under reduced pressure.
  • Example 044 Synthesis of (S)-2-amino-N-(7-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)butylamide To the compound (15.7 mg, 0. 039 mmol) of Example 047, anisole (100 ⁇ L) and trifluoroacetic acid (1 mL) were added and stirred at room temperature for one hour. After concentrated under reduced pressure, the reaction liquid was washed with isopropyl ether. After dissolved with 1M hydrochloric acid aqueous solution (1 mL), the residue was concentrated under reduced pressure again. Distilled water was added and the obtained aqueous solution was freeze-dried and hydrochloride salt (13.5 mg, quantitative) of the title compound was obtained.
  • Example 047 Synthesis of (S)-(1-(7-thiophen-2-yl-[1,2,4] triazolo[1,5-a]-pyrimidin-2-ylcarbamoyl)propyl)carbamic acid tert-butyl ester (example of Reaction Formula A)
  • (S)-2-(tert-butoxycarbonylamino)butyric acid (40.6 mg, 0.20mmol) and TFFH (50.0mg, 0.20 mmol) were dissolve in tetrahydrofuran (1 mL), added with N,N-diisopropylethylamine (69.7 ⁇ L, 0.40 mmol) and stirred at room temperature for one hour to prepared an acid fluoride.
  • Example 051 Synthesis of furan-2-carboxylic acid (7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl) amide (example of Reaction Formula A)
  • the compound of Reference Example 005 (96.5 mg, 0.40 mmol) was suspended in tetrahydrofuran (5 mL) and added with hexamethyldisilazane lithium salt (1M tetrahydrofuran solution, 0.80 mL) and stirred at room temperature for 5 minutes.
  • Furan-2-carboxylic acid chloride (40.0 ⁇ L, 0. 41 mmol) was added to this reaction liquid and stirred at room temperature for 10 minutes.
  • Example 054 Synthesis of 3-benzenesulfonyl-N-(7-(3-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propionamide
  • 3-(phenylsulfonyl) propionic acid 129 mg, 0.60 mmol
  • methylene chloride 2 mL
  • diisopropyl carbodiimide 47 ⁇ L, 0.30 mmol
  • the compound of Reference Example 8 (30.0 mg, 0.12 mmol) was dissolves in 1,3-dimethylimidazolidin-2-one (0.6 mL), added with the acid anhydride solution prepared above, and stirred at 100°C for 2.5 hours. Distilled water (13 mL), sodium chloride (0.5 g) and 6M aqueous sodium hydroxide (0.5 mmol) were added to the reaction liquid and the centrifugation supernatant was removed. The residue was suspended and washed with distilled water (10 mL x 2) and methylene chloride (8 mL x 2) successively and the title compound was obtained (19.2 mg, yield 37%).
  • Example 056 Synthesis of 3-benzenesulfonyl-N-(7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propionamide (example of Reaction Formula B) 3-(phenylsulfonyl) propionic acid (171.4 mg, 0.80 mmol) was suspended in methylene chloride (3 mL) and added with diisopropyl carbodiimide (62.6 ⁇ L, 0.40 mmol) and stirred at room temperature for 30 minutes to prepare an acid anhydride.
  • the compound of Reference Example 005 (48.3 mg, 0.20 mmol) was dissolves in 1,3-dimethylimidazolidin-2-one (0.8 mL), added with the acid anhydride solution prepared above, and stirred at 100°C for 3 hours. Distilled water (10 mL) was added to the reaction liquid and the centrifugation supernatant was removed. The residue was suspended and washed with 5% potassium carbonate aqueous solution (x 2), distilled water, 4M hydrochloric acid water (x 3) and distilled water successively and the title compound was obtained (25.2 mg, yield 29%).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP04792462A 2003-10-17 2004-10-15 Substituiertes 2-amino-[1,2,4]triazolo[1,5-a]pyrimidinderivat und dessen verwendung Withdrawn EP1674454A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003357143 2003-10-17
PCT/JP2004/015245 WO2005037837A1 (ja) 2003-10-17 2004-10-15 置換２−アミノ−[１，２，４]トリアゾロ[１，５−a]ピリミジン誘導体及びその用途

Publications (2)

Publication Number Publication Date
EP1674454A1 true EP1674454A1 (de) 2006-06-28
EP1674454A4 EP1674454A4 (de) 2006-12-27

Family

ID=34463237

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04792462A Withdrawn EP1674454A4 (de) 2003-10-17 2004-10-15 Substituiertes 2-amino-[1,2,4]triazolo[1,5-a]pyrimidinderivat und dessen verwendung

Country Status (5)

Country Link
US (1) US20070129383A1 (de)
EP (1) EP1674454A4 (de)
JP (1) JPWO2005037837A1 (de)
CA (1) CA2542290A1 (de)
WO (1) WO2005037837A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540821A1 (de) * 2010-02-23 2013-01-02 Nippon Kayaku Kabushiki Kaisha Verfahren zur herstellung regulatorischer dendritischer zellen

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
AU2005210474B2 (en) 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
KR101239541B1 (ko) * 2007-07-02 2013-03-06 아사히 가세이 메디컬 가부시키가이샤 미조리빈을 함유하는 궤양성 대장염 치료약
EP2277881A4 (de) * 2008-04-18 2011-09-07 Shionogi & Co Heterocyclische verbindung mit inhibierender wirkung auf p13k
US9657024B2 (en) 2012-11-21 2017-05-23 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
CA3196061A1 (en) 2020-10-23 2022-04-28 Ildong Pharmaceutical Co., Ltd. Cftr modulator compounds, compositions, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083485A1 (en) * 2000-04-28 2001-11-08 Bayer Aktiengesellschaft Imidazopyrimidine derivatives and triazolopyrimidine derivatives
WO2002020495A2 (en) * 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5827773B2 (ja) * 1980-02-08 1983-06-11 持田製薬株式会社 癌転移抑制剤
HU208693B (en) * 1991-02-22 1993-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them
JPH07309872A (ja) * 1994-03-24 1995-11-28 Otsuka Pharmaceut Factory Inc 縮環ピリミジン誘導体及び鎮痛剤
EP1307200A2 (de) * 2000-06-30 2003-05-07 Wyeth Substituierte triazolopyrimidine als antikrebsmittel
JP2004323458A (ja) * 2003-04-28 2004-11-18 Nippon Kayaku Co Ltd ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−２−イルアミン誘導体，その製造法及びその用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083485A1 (en) * 2000-04-28 2001-11-08 Bayer Aktiengesellschaft Imidazopyrimidine derivatives and triazolopyrimidine derivatives
WO2002020495A2 (en) * 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005037837A1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540821A1 (de) * 2010-02-23 2013-01-02 Nippon Kayaku Kabushiki Kaisha Verfahren zur herstellung regulatorischer dendritischer zellen
EP2540821A4 (de) * 2010-02-23 2013-08-14 Nippon Kayaku Kk Verfahren zur herstellung regulatorischer dendritischer zellen
AU2011221314B2 (en) * 2010-02-23 2015-05-14 National University Corporation Hokkaido University Method for preparing regulatory dendritic cells
RU2597976C2 (ru) * 2010-02-23 2016-09-20 Ниппон Каяку Кабусики Кайся Способ получения регуляторных дендритных клеток

Also Published As

Publication number Publication date
EP1674454A4 (de) 2006-12-27
WO2005037837A1 (ja) 2005-04-28
US20070129383A1 (en) 2007-06-07
CA2542290A1 (en) 2005-04-28
JPWO2005037837A1 (ja) 2006-12-28

Similar Documents

Publication Publication Date Title
KR101097479B1 (ko) [1,2,4]트리아졸로[1,5-ａ]피리미딘-2-일우레아 유도체와그 용도
US6951866B2 (en) Bicyclic pyrimidine compounds and therapeutic use thereof
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
US11873304B2 (en) Fused pyrimidine derivatives as A2A/A2B inhibitors
US10144737B2 (en) Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
US20050153992A1 (en) Pyrrolopyrimidine thion derivatives
JP4890723B2 (ja) ＴＮＦαインヒビターとして有用なクマリン誘導体
JP2009528296A (ja) Ｖａｌ−４によって媒介される白血球の接着を阻害するピリミジニルスルホンアミド化合物
JPH05508390A (ja) 多機能製剤化合物及びその使用法
US7557113B2 (en) Substituted pyrrolo[3,2-d]pyrimidine derivatives
US20070129383A1 (en) Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
US20220362259A1 (en) Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
US20230382911A1 (en) Pyrazoleamide derivatives
US8575165B2 (en) Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
JP2007509052A (ja) ケモカイン受容体活性のモジュレーターとしての新規三環式スピロ誘導体
US8334297B2 (en) 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
US20220313657A1 (en) Novel substituted sulfoximine derivatives
JP2004323458A (ja) ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−２−イルアミン誘導体，その製造法及びその用途
US20120115900A1 (en) Substituted naphthyridine derivatives and their medical use
US11992494B2 (en) Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
RU2797123C2 (ru) Низкомолекулярные модуляторы пантотенаткиназ
US20030064978A1 (en) Novel compounds
TW202028199A (zh) 作為蛋白激酶抑制劑的萘啶酮和吡啶基嘧啶酮類化合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060413

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/06 20060101ALI20060808BHEP

Ipc: A61P 9/00 20060101ALI20060808BHEP

Ipc: C07D 487/04 20060101AFI20060808BHEP

Ipc: A61P 1/16 20060101ALI20060808BHEP

Ipc: A61P 3/10 20060101ALI20060808BHEP

Ipc: A61P 1/04 20060101ALI20060808BHEP

Ipc: A61P 5/14 20060101ALI20060808BHEP

Ipc: A61K 31/519 20060101ALI20060808BHEP

Ipc: A61P 13/12 20060101ALI20060808BHEP

Ipc: A61K 9/06 20060101ALI20060808BHEP

Ipc: A61P 17/00 20060101ALI20060808BHEP

Ipc: A61P 7/04 20060101ALI20060808BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20061128

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: KURAMOCHI, HIROSHI

Inventor name: TOKUNAKA, KAZUHIRO

Inventor name: MASUDA, AKIRA

Inventor name: TOYODA, ERIKO

Inventor name: SHIMIZU, KAZUHISA

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MASUDA, AKIRA

Inventor name: KURAMOCHI, HIROSHI

Inventor name: TOYODA, ERIKO

Inventor name: TOKUNAKA, KAZUHIRO

Inventor name: SHIMIZU, KAZUHISA

17Q First examination report despatched

Effective date: 20071219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080430